research Inflammasome Proteins as Biomarkers of Injury and Disease
Inflammasome proteins can indicate the severity and treatment response of various diseases and injuries.
Search
for
Sort by
Research
720-750 / 1000+ results 
research 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
SIG-1451 could be a promising new treatment for atopic dermatitis.
research Decision letter: Involvement of ILC1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata
ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.
research The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications
Alopecia areata severity and treatment response are linked to specific cytokine levels.
research Distribution of human B-defensin 2, TNF-alpha, IL-1 alpha, IL-6 and IL-8 in psoriatic skin
Certain proteins and cytokines are key in causing psoriatic skin issues.
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research 489 Seborrhea-like dermatitis phenotype in the Mpzl3 knockout mice
MPZL3 is crucial for seborrheic dermatitis development.
research Type 1 interferon signature in the scalp lesions of alopecia areata
Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.
research A clinical case of familial alopecia areata in combination with immune pathology
Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
research The role of natural killer cells in autoimmune blistering diseases
Natural killer cells play a key role in autoimmune skin diseases like pemphigus vulgaris.
research Association of Serum IL-17A and IL-23 Levels With Alopecia Areata: A Cross-Sectional Comparative Study
Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
research Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
research Ligand-Dependent Actions of the Vitamin D Receptor Are Required for Activation of TGF-β Signaling during the Inflammatory Response to Cutaneous Injury
Vitamin D receptor is essential for proper skin healing after injury.
research The spectrum of inflammatory skin disease following jejuno-ileal bypass for morbid obesity
Some patients developed skin inflammation after obesity surgery, and a medication called dapsone helped treat it.
research Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature
Mice with extra human KLK14 had hair and skin problems, including weaker cell bonds and inflammation, linked to Netherton syndrome.
research Activation of TRPV3 Inhibits Lipogenesis and Stimulates Production of Inflammatory Mediators in Human Sebocytes—A Putative Contributor to Dry Skin Dermatoses
Activating TRPV3 reduces skin oil production and increases inflammation, potentially causing dry skin issues.
research Abstract 4300: Constitutive activation of Stat3 increases hair follicle progenitor population at the expense of bulge region keratinocyte stem cells
Stat3 activation increases hair follicle progenitors but reduces bulge region stem cells.
research 1379 Cyclosporin A suppresses TGF-β2 expression via calcineurin/NFAT pathway in human dermal papilla cells
Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
research Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
research Complete Blood Collection-based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-sectional Study
Higher inflammation markers are linked to more severe alopecia areata.
research Cutaneous Drug Reaction Case Reports
Various drugs caused different skin reactions, including allergic and inflammatory responses.
research 259 Immunohistochemical insight into the association between the collapse of immune privilege in the sweat gland and syringotropic immune cell infiltrates in collagen diseases
The study found that sweat glands normally suppress immune responses, but this is disrupted in certain skin diseases, possibly contributing to their development.
research Episodes of Keratitis during Treatment with Baricitinib for Alopecia Areata
Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
research 057 Single cell RNA and TCR sequencing reveals hyperexpansion of T cell clones and novel regulatory mechanisms of CD8+ T cells in murine alopcecia areata skin and draining lymph nodes
research SnapshotDx Quiz: February 2018
Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.
research At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
research Janus kinase inhibitors: An innovative treatment for alopecia areata
New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.